1.Luo, J, et al. Meta-analysis on the relationship between HLA-DRB1 gene polymorphism and chronic hepatitis B in Chinese population. World Chinese Journal of Digestology 2006; 14: 3050–3054.
2.Qian, YH, et al. Review of the relationship between HLA_DR, DQ genes and chronic hepatitis B. Modern Preventive Medicine 2009; 36: 131–133.
3.York, IA, Rock, KL. Antigen processing and presentation by the class I major histocompatibility complex. Annual Review of Immunology 1996; 14: 369–396.
4.Heemels, MT, Ploegh, H. Generation, translocation, and presentation of MHC class I-restricted peptides. Annual Review of Biochemistry 1995; 64: 463–491.
5.Driscoll, J, et al. MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature 1993; 365: 262–264.
6.Gaczynska, M, Rock, KL, Goldberg, AL. Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 1993; 365: 264–267.
7.Neefjes, JJ, Momburg, F, Hammerling, GJ. Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science 1993; 261: 769–771.
8.Shepherd, JC, et al. TAP1-dependent peptide translocation in vitro is ATP dependent and peptide selective. Cell 1993; 74: 577–584.
9.Cromme, FV, et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. Journal of Experimental Medicine 1994; 179: 335–340.
10.Seliger, B, Maeurer, MJ, Ferrone, S. TAP off-tumors on. Immunology Today 1997; 18: 292–299.
11.Cao, B, et al. LMP7/TAP2 gene polymorphisms and HPV infection in esophageal carcinoma patients from a high incidence area in China. Carcinogenesis 2005; 26: 1280–1284.
12.McTernan, CL, et al. Assessment of the non-HLA-DR-DQ contribution to IDDM1 in British Caucasian families: analysis of LMP7 polymorphisms. Diabetic Medicine 2000; 17: 661–666.
13.Prahalad, S, et al. Polymorphism in the MHC-encoded LMP7 gene: association with JRA without functional significance for immunoproteasome assembly. Journal of Rheumatology 2001; 28: 2320–2325.
14.Vargas-Alarcon, G, et al. Association study of LMP gene polymorphisms in Mexican patients with spondyloarthritis. Human Immunology 2004; 65: 1437–1442.
15.Khu, YL, et al. Hepatitis C virus non-structural protein NS3 interacts with LMP7, a component of the immunoproteasome, and affects its proteasome activity. Biochemical Journal 2004; 384: 401–409.
16.Lautscham, G, Rickinson, A, Blake, N. TAP-independent antigen presentation on MHC class I molecules: lessons from Epstein-Barr virus. Microbes and Infection 2003; 5: 291–299.
17.Neumeister, C, et al. Measles virus and canine distemper virus target proteins into a TAP-independent MHC class I-restricted antigen-processing pathway. Journal of General Virology 2001; 82: 441–447.
18.Taniuchi, S, et al. Polymorphism of Fc gamma RIIa may affect the efficacy of gamma-globulin therapy in Kawasaki disease. Journal of Clinical Immunology 2005; 25: 309–313.
19.Van Belzen, MJ, et al. CTLA4+49 A/G and CT60 polymorphisms in Dutch coeliac disease patients. European Journal of Human Genetics 2004; 12: 782–785.
20.Stephens, M, Smith, NJ, Donnelly, P. A new statistical method for haplotype reconstruction from population data. American Journal of Human Genetics 2001; 68: 978–989.
21.Dai, Y, et al. Association between LMP2/LMP7 gene polymorphism and the infection of hepatitis B virus. Journal of Peking University 2005; 37: 508–512.
22.Tang, J, et al. Genotyping TAP2 variants in North American Caucasians, Brazilians, and Africans. Genes and Immunity 2001; 2: 32–40.
23.Witkowska-Tobola, AM, et al. Polymorphism of the TAP1 gene in Polish patients with psoriasis vulgaris. Journal of Applied Genetics 2004; 45: 391–393.
24.Jung, MC, Pape, GR. Immunology of hepatitis B infection. Lancet Infectious Diseases 2002; 2: 43–50.
25.Xu, C, et al. Genetic polymorphisms of LMP/TAP gene and hepatitis B virus infection risk in the Chinese population. Journal of Clinical Immunology 2007; 27: 534–541.
26.McCluskey, J, Rossjohn, J, Purcell, AW. TAP genes and immunity. Current Opinion in Immunology 2004; 16: 651–659.
27.Obst, R, et al. TAP polymorphism does not influence transport of peptide variants in mice and humans. European Journal of Immunology 1995; 25: 2170–2176.
28.Quadri, SA, Singal, DP. Peptide transport in human lymphoblastoid and tumor cells: effect of transporter associated with antigen presentation (TAP) polymorphism. Immunology Letters 1998; 61: 25–31.
29.Daniel, S, et al. Absence of functional relevance of human transporter associated with antigen processing polymorphism for peptide selection. Journal of Immunology 1997; 159: 2350–2357.
30.Sugimoto, Y, et al. A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C. Journal of Viral Hepatitis 2002; 9: 377–384.
31.Sijts, AJ, et al. Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes. Journal of Experimental Medicine 2000; 191: 503–514.
32.Judson, R, Stephens, JC. Notes from the SNP vs. haplotype front. Pharmacogenomics 2001; 2: 7–10.
33.Judson, R, Stephens, JC, Windemuth, A. The predictive power of haplotypes in clinical response. Pharmacogenomics 2000; 1: 15–26.
34.Sun, T, et al. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. Journal of National Cancer Institute 2004; 96: 1030–1036.
35.Zhang, X, et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. Journal of Medical Genetics 2005; 42: 479–484.